Auris Medical's Tinnitus Candidate Keyzilen Fails Second Phase III Trial

Auris Medical has acknowledged the second Phase III failure in 19 months for its tinnitus candidate Keyzilen ® (AM-101), promising a future update on its plans for the company’s co-lead development program.Auris said Keyzilen failed the TACTT3 trial ( NCT02040194 ) by missing its primary efficacy endpoint of a statistically significant improvement in the Tinnitus Functional Score from baseline to day 84 in participants treated with the drug compared to those treated with placebo, eithe